On September 8, 2017 CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody therapeutics for the treatment of cancer, reported upcoming Trials in Progress poster presentations for its two lead product candidates, CX-072, a PD-L1 targeting Probody therapeutic and CX-2009, a Probody-drug conjugate targeting CD166, at the European Society for Medical Oncology Annual Meeting from September 8-12 in Madrid, Spain (Press release, CytomX Therapeutics, SEP 8, 2017, View Source;p=RssLanding&cat=news&id=2299537 [SID1234520427]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Know more, wherever you are:
Latest on ESMO (Free ESMO Whitepaper) Through 1stOncology, book your free 1stOncology demo here.
Abstract Information:
Title: The First-in-Human, Dose-Finding PROCLAIM-CX-072 Trial to Assess the Antitumor Activity and Tolerability of the Probody
Therapeutic CX-072 as Monotherapy and in Combination With Ipilimumab or Vemurafenib in Solid Advanced Tumors and Lymphomas
Author: Valentina Boni, M.D., Ph.D., START Madrid-CIOCC, Madrid, Spain
Date: Monday, September 11, 2017
Time: 1:15 p.m. – 2:15 p.m.
Location: Hall 8
Abstract: 423TiP
About the PROCLAIM-CX-072 Trial:
The PROCLAIM-CX-072 (PRObody CLinical Assessment In Man) study is designed to evaluate tolerability, and preliminary antitumor activity and translational biomarkers of multiple doses of CX-072 as monotherapy or as combination therapy with ipilimumab or vemurafenib in patients with advanced, unresectable solid tumors or lymphoma. This first-in-human, open-label, multicenter, dose-escalation, phase 1/2 study of CX-072 includes 4 dose-escalation groups (monotherapy, Part A; 2 ipilimumab combination schedules, Parts B1 and B2; vemurafenib combination, Part C), a stage testing biomarkers and efficacy in PD-L1+ tumors (Part A2), and a dose-expansion phase (Part D).
Abstract Information:
Title: PROCLAIM-CX-2009: A First-in-Human Trial to Evaluate CX-2009 in Adults With Metastatic or Locally Advanced Unresectable Solid Tumors
Author: Javier Garcia-Corbacho M.D., Hospital Clinic Barcelona, Barcelona, Spain
Date: Monday, September 11, 2017
Time: 1:15 p.m. – 2:15 p.m.
Location: Hall 8
Abstract: 422TiP
About the PROCLAIM-CX-2009 Trial:
The objectives of the ongoing PROCLAIM-CX-2009 (PRObody CLinical Assessment In Man) module are to determine the maximum tolerated dose (MTD), recommended phase 2 dose (RP2D), dose-limiting toxicities, and preliminary antitumor activity of CX-2009 as monotherapy in the following 7 selected tumor types with high CD166 expression: breast carcinoma, castration-resistant prostate carcinoma (CRPC), cholangiocarcinoma, endometrial carcinoma, epithelial ovarian carcinoma, head and neck squamous cell carcinoma (HNSCC), and non–small cell lung carcinoma (NSCLC).